496 related articles for article (PubMed ID: 28743264)
1. Recent developments in immunotherapy of acute myeloid leukemia.
Lichtenegger FS; Krupka C; Haubner S; Köhnke T; Subklewe M
J Hematol Oncol; 2017 Jul; 10(1):142. PubMed ID: 28743264
[TBL] [Abstract][Full Text] [Related]
2. An Update on the Clinical Evaluation of Antibody-Based Therapeutics in Acute Myeloid Leukemia.
Venugopal S; Daver N; Ravandi F
Curr Hematol Malig Rep; 2021 Feb; 16(1):89-96. PubMed ID: 33630233
[TBL] [Abstract][Full Text] [Related]
3. Harnessing the Immune System Against Leukemia: Monoclonal Antibodies and Checkpoint Strategies for AML.
Masarova L; Kantarjian H; Garcia-Mannero G; Ravandi F; Sharma P; Daver N
Adv Exp Med Biol; 2017; 995():73-95. PubMed ID: 28321813
[TBL] [Abstract][Full Text] [Related]
4. Immune-Based Therapeutic Interventions for Acute Myeloid Leukemia.
Perna F; Espinoza-Gutarra MR; Bombaci G; Farag SS; Schwartz JE
Cancer Treat Res; 2022; 183():225-254. PubMed ID: 35551662
[TBL] [Abstract][Full Text] [Related]
5. Immunotherapy in acute myeloid leukemia and myelodysplastic syndromes: The dawn of a new era?
Liu Y; Bewersdorf JP; Stahl M; Zeidan AM
Blood Rev; 2019 Mar; 34():67-83. PubMed ID: 30553527
[TBL] [Abstract][Full Text] [Related]
6. The progress and current status of immunotherapy in acute myeloid leukemia.
Yang D; Zhang X; Zhang X; Xu Y
Ann Hematol; 2017 Dec; 96(12):1965-1982. PubMed ID: 29080982
[TBL] [Abstract][Full Text] [Related]
7. Immunotherapy for Acute Myeloid Leukemia.
Lichtenegger FS; Krupka C; Köhnke T; Subklewe M
Semin Hematol; 2015 Jul; 52(3):207-14. PubMed ID: 26111468
[TBL] [Abstract][Full Text] [Related]
8. Acute myeloid leukemia and novel biological treatments: monoclonal antibodies and cell-based gene-modified immune effectors.
Tettamanti S; Magnani CF; Biondi A; Biagi E
Immunol Lett; 2013; 155(1-2):43-6. PubMed ID: 24076117
[TBL] [Abstract][Full Text] [Related]
9. Targeting human C-type lectin-like molecule-1 (CLL1) with a bispecific antibody for immunotherapy of acute myeloid leukemia.
Lu H; Zhou Q; Deshmukh V; Phull H; Ma J; Tardif V; Naik RR; Bouvard C; Zhang Y; Choi S; Lawson BR; Zhu S; Kim CH; Schultz PG
Angew Chem Int Ed Engl; 2014 Sep; 53(37):9841-5. PubMed ID: 25056598
[TBL] [Abstract][Full Text] [Related]
10. Overcoming target epitope masking resistance that can occur on low-antigen-expresser AML blasts after IL-1RAP chimeric antigen receptor T cell therapy using the inducible caspase 9 suicide gene safety switch.
Warda W; Da Rocha MN; Trad R; Haderbache R; Salma Y; Bouquet L; Roussel X; Nicod C; Deschamps M; Ferrand C
Cancer Gene Ther; 2021 Dec; 28(12):1365-1375. PubMed ID: 33414517
[TBL] [Abstract][Full Text] [Related]
11. CD38-directed CAR-T cell therapy: a novel immunotherapy strategy for relapsed acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation.
Cui Q; Qian C; Xu N; Kang L; Dai H; Cui W; Song B; Yin J; Li Z; Zhu X; Qu C; Liu T; Shen W; Zhu M; Yu L; Wu D; Tang X
J Hematol Oncol; 2021 May; 14(1):82. PubMed ID: 34034795
[TBL] [Abstract][Full Text] [Related]
12. Immunotherapies in acute leukemia.
Boissel N; Rabian F
Therapie; 2022; 77(2):241-250. PubMed ID: 34924207
[TBL] [Abstract][Full Text] [Related]
13. CD33-directed immunotherapy with third-generation chimeric antigen receptor T cells and gemtuzumab ozogamicin in intact and CD33-edited acute myeloid leukemia and hematopoietic stem and progenitor cells.
Liu Y; Wang S; Schubert ML; Lauk A; Yao H; Blank MF; Cui C; Janssen M; Schmidt C; Göllner S; Kleist C; Zhou F; Rahfeld JU; Sauer T; Schmitt M; Müller-Tidow C
Int J Cancer; 2022 Apr; 150(7):1141-1155. PubMed ID: 34766343
[TBL] [Abstract][Full Text] [Related]
14. Emerging Immunotherapy for Acute Myeloid Leukemia.
Tabata R; Chi S; Yuda J; Minami Y
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33669431
[TBL] [Abstract][Full Text] [Related]
15. Current strategies in immunotherapy for acute myeloid leukemia.
Lichtenegger FS; Schnorfeil FM; Hiddemann W; Subklewe M
Immunotherapy; 2013 Jan; 5(1):63-78. PubMed ID: 23256799
[TBL] [Abstract][Full Text] [Related]
16. Emerging antibody-based therapies for the treatment of acute myeloid leukemia.
Angenendt L; Mikesch JH; Schliemann C
Cancer Treat Rev; 2022 Jul; 108():102409. PubMed ID: 35605472
[TBL] [Abstract][Full Text] [Related]
17. A novel IgG-based FLT3xCD3 bispecific antibody for the treatment of AML and B-ALL.
Mehta NK; Pfluegler M; Meetze K; Li B; Sindel I; Vogt F; Marklin M; Heitmann JS; Kauer J; Osburg L; Zekri L; Bühring HJ; Mueller S; Hörner S; Baeuerle PA; Michaelson JS; Jung G; Salih HR
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35288466
[TBL] [Abstract][Full Text] [Related]
18. T-cell-based immunotherapy of acute myeloid leukemia: current concepts and future developments.
Daver N; Alotaibi AS; Bücklein V; Subklewe M
Leukemia; 2021 Jul; 35(7):1843-1863. PubMed ID: 33953290
[TBL] [Abstract][Full Text] [Related]
19. Immunotherapeutic Concepts to Target Acute Myeloid Leukemia: Focusing on the Role of Monoclonal Antibodies, Hypomethylating Agents and the Leukemic Microenvironment.
Gbolahan OB; Zeidan AM; Stahl M; Abu Zaid M; Farag S; Paczesny S; Konig H
Int J Mol Sci; 2017 Jul; 18(8):. PubMed ID: 28758974
[TBL] [Abstract][Full Text] [Related]
20. Systematic preclinical evaluation of CD33-directed chimeric antigen receptor T cell immunotherapy for acute myeloid leukemia defines optimized construct design.
Qin H; Yang L; Chukinas JA; Shah N; Tarun S; Pouzolles M; Chien CD; Niswander LM; Welch AR; Taylor N; Tasian SK; Fry TJ
J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34531250
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
